BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects

Bruton´s tyrosine kinase (BTK) inhibitor (BTKi)s block the B-cell receptor (BCR) signaling cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant and normal B cells. During the past decade, the clinical use of BTKis for the treatment of B-cell malignancies has ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Palma, Marzia, Mulder, Tom A., Österborg, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282344/
https://www.ncbi.nlm.nih.gov/pubmed/34276674
http://dx.doi.org/10.3389/fimmu.2021.686768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282344/
https://www.ncbi.nlm.nih.gov/pubmed/34276674
http://dx.doi.org/10.3389/fimmu.2021.686768

Ejemplares similares